排序方式: 共有13条查询结果,搜索用时 15 毫秒
1.
2.
3.
Mohammad S. Siddiqui Raj Vuppalanchi Mark L. Van Natta Erin Hallinan Kris V. Kowdley Manal Abdelmalek Brent A. Neuschwander-Tetri Rohit Loomba Srinivasan Dasarathy Danielle Brandman Edward Doo James A. Tonascia David E. Kleiner Naga Chalasani Arun J. Sanyal 《Clinical gastroenterology and hepatology》2019,17(1):156-163.e2
4.
Mohammad Shadab Siddiqui Salvatore Carbone Robert Vincent Samarth Patel Carolyn Driscoll Francesco S. Celi Hayley Billingsley Brando Rotelli Binu John Nicola Potere Michele Viscusi Veronica Adiletta Arun J. Sanyal Velimir A. Luketic Trevor Reichman Chandra S. Bhati 《Clinical gastroenterology and hepatology》2019,17(10):2132-2133
5.
6.
7.
PurposeNonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and has the potential risk for progressing to nonalcoholic steatohepatitis (NASH), which is associated with a greater risk for complications of chronic liver disease. Noninvasive testing has been evaluated for diagnosis, risk stratification, disease progression, and assessing response to therapy. The purpose of this narrative review was to outline the current noninvasive testing modalities for the diagnostic evaluation of NAFLD and NASH, while discussing possible markers that could be used for monitoring response to therapies.MethodsThe PubMed and Cochrane databases were searched for relevant articles that evaluated the diagnosis of NAFLD/NASH with serum biomarkers and/or imaging.FindingsSerum biomarkers, imaging modalities, and combinations/serial algorithms involved in the diagnosis of NAFLD and NASH are outlined. In addition, noninvasive modalities that have been used for assessing response to therapies in clinical trials are discussed.ImplicationsLiver biopsy currently remains the gold standard for diagnosis and is often used in clinical trials to assess treatment response. However, developing safe and accessible noninvasive modalities for diagnosis and monitoring will have greater impact and relevance, as biopsy may not always be feasible in all clinical settings. 相似文献
8.
9.
10.
Cécile Bastard Véronique Miette Paul Calès Horia Stefanescu Davide Festi Laurent Sandrin 《Ultrasound in medicine & biology》2018,44(8):1616-1626
Esophageal varices (EVs) are among the most severe complications of cirrhosis, with a prevalence of 50% to 60% among cirrhotic patients. International guidelines therefore recommend that cirrhotic patients should be screened for the presence of EVs. The main objective of this study was to introduce a new spleen-dedicated FibroScan (Echosens, Paris, France) examination and to assess its performance in detecting large EVs (grade 2 and 3). This novel examination has been validated in simulation and phantom studies and has been used in a population of patients with chronic liver disease. The study described here suggests that the novel spleen-dedicated FibroScan examination performs better than the standard FibroScan for the detection of large EVs (area under the curve?=?0.70 for the standard examination and 0.79 [p?<0.01] for the spleen examination), but further clinical studies are needed to investigate the role of spleen stiffness in the management of cirrhotic patients. 相似文献